{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:31Z","timestamp":1759451971102,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T02:35:50Z","timestamp":1613874950000},"page":"1609-1620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses"],"prefix":"10.1016","volume":"39","author":[{"given":"Danmin","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafeng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianying","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiping","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.02.002_b0005","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4155\/tde.11.68","article-title":"Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems","volume":"2","author":"Foged","year":"2011","journal-title":"Ther Deliv"},{"key":"10.1016\/j.vaccine.2021.02.002_b0010","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201200487","article-title":"Modern subunit vaccines: development, components, and research opportunities","volume":"8","author":"Moyle","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.vaccine.2021.02.002_b0015","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.02.002_b0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00262-016-1834-5","article-title":"Designing therapeutic cancer vaccines by mimicking viral infections","volume":"66","author":"Sultan","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2021.02.002_b0025","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.4049\/jimmunol.1102696","article-title":"The importance of adjuvant formulation in the development of a tuberculosis vaccine","volume":"188","author":"Baldwin","year":"2012","journal-title":"J Immunol"},{"issue":"Suppl 4","key":"10.1016\/j.vaccine.2021.02.002_b0030","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1038\/nm1210","article-title":"Targeting the innate immune response with improved vaccine adjuvants","volume":"11","author":"Pashine","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.02.002_b0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.02.002_b0040","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.02.002_b0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.imlet.2011.05.005","article-title":"ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime\/peptide boost strategy: GM-CSF induced long-lived memory responses","volume":"140","author":"Mahdavi","year":"2011","journal-title":"Immunol Lett"},{"key":"10.1016\/j.vaccine.2021.02.002_b0050","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.cr.7310017","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know","volume":"16","author":"Shi","year":"2006","journal-title":"Cell Res"},{"key":"10.1016\/j.vaccine.2021.02.002_b0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/COC.0b013e31827def82","article-title":"Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study","volume":"37","author":"Grotz","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0060","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-016-1860-3","article-title":"Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma","volume":"65","author":"Hoeller","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2021.02.002_b0065","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.4049\/jimmunol.1001855","article-title":"Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88","volume":"186","author":"Bates","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0070","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3390\/toxins7030974","article-title":"Cholera toxin B: one subunit with many pharmaceutical applications","volume":"7","author":"Baldauf","year":"2015","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.vaccine.2021.02.002_b0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.actbio.2014.09.019","article-title":"Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity","volume":"11","author":"Jiang","year":"2015","journal-title":"Acta Biomater"},{"key":"10.1016\/j.vaccine.2021.02.002_b0080","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/eji.200324135","article-title":"Cholera toxin activates dendritic cells through dependence on GM1-ganglioside which is mediated by NF-kappaB translocation","volume":"33","author":"Kawamura","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0085","doi-asserted-by":"crossref","first-page":"42372","DOI":"10.1038\/srep42372","article-title":"Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice","volume":"7","author":"Posgai","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2021.02.002_b0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nano.2018.01.002","article-title":"Uptake and intracellular fate of cholera toxin subunit b-modified mesoporous silica nanoparticle-supported lipid bilayers (aka protocells) in motoneurons","volume":"14","author":"Gonzalez Porras","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.vaccine.2021.02.002_b0095","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00262-012-1379-1","article-title":"Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine","volume":"62","author":"Noguchi","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.vaccine.2021.02.002_b0100","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00262-017-2042-7","article-title":"Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody","volume":"66","author":"Muthumani","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2021.02.002_b0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pep.2016.03.007","article-title":"Purification and characterization of a novel cell-penetrating carrier similar to cholera toxin chimeric protein","volume":"129","author":"Lin","year":"2017","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2021.02.002_b0110","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3109\/08820130903124770","article-title":"Immunotherapy of autoimmune diabetes by nasal administration of tendem glutamic acid decarboxylase 65 peptides","volume":"38","author":"Wang","year":"2009","journal-title":"Immunol Invest"},{"key":"10.1016\/j.vaccine.2021.02.002_b0115","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaut.2008.08.010","article-title":"GM-CSF induces STAT5 binding at epigenetic regulatory sites within the Csf2 promoter of non-obese diabetic (NOD) mouse myeloid cells","volume":"31","author":"Seydel","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.vaccine.2021.02.002_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046981","article-title":"Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector","volume":"7","author":"Williams","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.02.002_b0125","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/pros.20942","article-title":"Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer","volume":"69","author":"Kim","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.vaccine.2021.02.002_b0130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmbi.1995.0456","article-title":"The three-dimensional crystal structure of cholera toxin","volume":"251","author":"Zhang","year":"1995","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0135","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/mr.56.4.622-647.1992","article-title":"Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin","volume":"56","author":"Spangler","year":"1992","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.02.002_b0140","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.4049\/jimmunol.169.7.3574","article-title":"Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF","volume":"169","author":"Lutz","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0145","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/mi.2014.11","article-title":"The development and function of mucosal lymphoid tissues: a balancing act with micro-organisms","volume":"7","author":"Randall","year":"2014","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0150","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mi.2013.30","article-title":"Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium","volume":"6","author":"Mabbott","year":"2013","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0155","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ni.1838","article-title":"Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza","volume":"11","author":"Ballesteros-Tato","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0160","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.26.021607.090254","article-title":"Migration of dendritic cell subsets and their precursors","volume":"26","author":"Randolph","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jconrel.2020.03.027","article-title":"An in vitro and in vivo study of the brain-targeting effects of an epidermal growth factor-functionalized cholera toxin-like chimeric protein","volume":"322","author":"He","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2021.02.002_b0170","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1073\/pnas.85.19.7109","article-title":"Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro","volume":"85","author":"Hardy","year":"1988","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2021.02.002_b0175","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.immuni.2015.11.006","article-title":"Toll-like receptor 4 engagement on dendritic cells restrains phago-lysosome fusion and promotes cross-presentation of antigens","volume":"43","author":"Alloatti","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2021.02.002_b0180","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/s41467-018-04814-4","article-title":"Association between post-diagnostic use of cholera vaccine and risk of death in prostate cancer patients","volume":"9","author":"Ji","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2021.02.002_b0185","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/eji.200324368","article-title":"Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor","volume":"34","author":"Eriksson","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0190","first-page":"3340","article-title":"Growth inhibition by cholera toxin of human lung carcinoma cell lines: correlation with GM1 ganglioside expression","volume":"52","author":"Kaur","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2021.02.002_b0195","doi-asserted-by":"crossref","unstructured":"Ho NI, Huis In 't Veld LGM, Raaijmakers TK, Adema GJ. Adjuvants enhancing cross-presentation by dendritic cells: The Key to More Effective Vaccines? Front Immunol 2018;9:2874.","DOI":"10.3389\/fimmu.2018.02874"},{"key":"10.1016\/j.vaccine.2021.02.002_b0200","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1084\/jem.180.2.631","article-title":"Comparative analysis of B7\u20131 and B7\u20132 costimulatory ligands: expression and function","volume":"180","author":"Hathcock","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.02.002_b0205","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00262-006-0198-7","article-title":"Addition of GM-CSF to a peptide\/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells","volume":"56","author":"Na","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2021.02.002_b0210","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1007\/s00253-017-8370-x","article-title":"The recombinant fusion protein of cholera toxin B and neutrophil-activating protein expressed on Bacillus subtilis spore surface suppresses allergic inflammation in mice","volume":"101","author":"Dong","year":"2017","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0215","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.4049\/jimmunol.177.11.7634","article-title":"Oral tolerance induction with antigen conjugated to cholera toxin B subunit generates both Foxp3+CD25+ and Foxp3-CD25- CD4+ regulatory T cells","volume":"177","author":"Sun","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0220","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1073\/pnas.1620194114","article-title":"Nasal-associated lymphoid tissues (NALTs) support the recall but not priming of influenza virus-specific cytotoxic T cells","volume":"114","author":"Pizzolla","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.vaccine.2021.02.002_b0225","doi-asserted-by":"crossref","first-page":"8451","DOI":"10.1016\/j.vaccine.2011.07.077","article-title":"Cholera toxin B subunit linked to glutamic acid decarboxylase suppresses dendritic cell maturation and function","volume":"29","author":"Odumosu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.002_b0230","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2567.2005.02246.x","article-title":"Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein","volume":"116","author":"Gockel","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2021.02.002_b0235","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellimm.2013.09.006","article-title":"Cholera toxin breakdowns oral tolerance via activation of canonical NF-\u03baB","volume":"285","author":"Kim","year":"2013","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0240","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.4049\/jimmunol.167.9.5386","article-title":"Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization","volume":"167","author":"Staats","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0245","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.4049\/jimmunol.154.9.4322","article-title":"Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2\/B subunits","volume":"154","author":"Hajishengallis","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0250","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri2817","article-title":"Prostate cancer as a model for tumour immunotherapy","volume":"10","author":"Drake","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0255","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1056\/NEJMoa051931","article-title":"Autoantibody signatures in prostate cancer","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.02.002_b0260","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","article-title":"Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases","volume":"82","author":"Bostwick","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2021.02.002_b0265","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","article-title":"Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: A phase 2 clinical trial","volume":"4","author":"Autio","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.vaccine.2021.02.002_b0270","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00262-017-2027-6","article-title":"Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer","volume":"66","author":"Sonpavde","year":"2017","journal-title":"Cancer Immuno Immunother"},{"key":"10.1016\/j.vaccine.2021.02.002_b0275","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","article-title":"Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives","volume":"45","author":"Backhaus","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.vaccine.2021.02.002_b0280","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13550-015-0104-4","article-title":"Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors","volume":"5","author":"Pandit-Taskar","year":"2015","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.vaccine.2021.02.002_b0285","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.vaccine.2021.02.002_b0290","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2021.02.002_b0295","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.vaccine.2018.05.010","article-title":"Hyperthermic treatment at 56\u2103 induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens","volume":"36","author":"De Sanctis","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.02.002_b0300","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1158\/1078-0432.CCR-07-5048","article-title":"Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy","volume":"14","author":"Madan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2021.02.002_b0305","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00262-012-1257-x","article-title":"Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer","volume":"61","author":"Hannan","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2021.02.002_b0310","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2017.12.008","article-title":"Efficacy against human prostate cancer by prostate-specific membrane antigen-specific, transforming growth factor-\u03b2 insensitive genetically targeted CD8+ T-cells derived from patients with metastatic castrate-resistant disease","volume":"73","author":"Zhang","year":"2018","journal-title":"Eur Urol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21001316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:38Z","timestamp":1759402358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21001316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21001316"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-delivery of PSMA antigen epitope and mGM-CSF with a cholera toxin-like chimeric protein suppressed prostate tumor growth via activating dendritic cells and promoting CTL responses","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}